Publications by the researcher in collaboration with Hernando Knobel (29)

2021

  1. Healthcare delivery for HIV-positive people with tuberculosis in Europe

    HIV Medicine, Vol. 22, Núm. 4, pp. 283-293

2020

  1. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

    Clinical Microbiology and Infection, Vol. 26, Núm. 11, pp. 1525-1536

2019

  1. Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 151-159

  2. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 195-202

  3. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

    Antiviral Research, Vol. 170

2018

  1. Barriers to health care services for migrants living with HIV in Spain

    European Journal of Public Health, Vol. 28, Núm. 3, pp. 451-457

  2. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

    The Lancet HIV, Vol. 5, Núm. 1, pp. e23-e34

2017

  1. Análisis de costes y de coste/eficacia de las pautas recomendadas por GESIDA/Plan Nacional sobre el Sida en 2016 para el tratamiento antirretroviral inicial en adultos infectados por el VIH

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 35, Núm. 2, pp. 88-99

  2. Dual Therapy with Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy with Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial

    Clinical Infectious Diseases, Vol. 65, Núm. 12, pp. 2112-2118

2016

  1. Executive summary: Prevención y tratamiento de infecciones oportunistas y otras coinfecciones en pacientes infectados por el VIH: mayo de 2015

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 34, Núm. 8, pp. 517-523

  2. Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 34, Núm. 8, pp. 516.e1-516.e18

2015

  1. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

  2. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792

  3. Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015)

    Enfermedades infecciosas y microbiologia clinica

  4. Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe

    HIV Medicine, Vol. 16, Núm. 9, pp. 544-552

  5. Virological failure to raltegravir in Spain: Incidence, prevalence and clinical consequences

    Journal of Antimicrobial Chemotherapy, Vol. 70, Núm. 11, pp. 3087-3095

2014

  1. Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: A multicentre experience in antiretroviral therapy-naive and -experienced patients

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 9

  2. Consensus document on the management of renal disease in HIV-infected patients

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia

  3. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: Same results as in clinical trials? The PIMOCS study group

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 5, pp. 1390-1396

  4. Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 9, pp. 583-597